Sikerült megtalálnunk az eredeti 1940-es kutatást, ahol először izolálták a CBD-t:
Roger Adams, Madison Hunt, and J. H. Clark (1940): Structure of Cannabidiol, a Product Isolated from the Marihuana Extract of Minnesota Wild Hemp. I, Journal of the American Chemical Society 1940 62 (1), 196-200
Az Endokannabioid rendszerről részletesebben:
Zou, Shenglong, and Ujendra Kumar. 2018. “Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System” International Journal of Molecular Sciences 19, no. 3: 833.
Az ’összhatás effektus’
Ethan B Russo (2011): Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects, British Journal of Pharmacology (2011) 163 1344–1364
Hložek T, Uttl L, Kadeřábek L, Balíková M, Lhotková E, Horsley RR, Nováková P, Šíchová K, Štefková K, Tylš F, Kuchař M, Páleníček T. (2017): Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC. Eur Neuropsychopharmacol. 2017 Dec;27(12):1223-1237.
Gerhard Nahler, Trevor M Jones, Ethan B Russo (2019): Cannabidiol and Contributions of Major Hemp Phytocompounds to the “Entourage Effect”; Possible Mechanisms, Nahler G, et al., J Altern Complement Integr Med 2019, 5: 070
Ferber SG, Namdar D, Hen-Shoval D, Eger G, Koltai H, Shoval G, Shbiro L, Weller A. (2020): The “Entourage Effect”: Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders. Curr Neuropharmacol. 2020;18(2):87-96.
Blasco-Benito S, Seijo-Vila M, Caro-Villalobos M, Tundidor I, Andradas C, García-Taboada E, Wade J, Smith S, Guzmán M, Pérez-Gómez E, Gordon M, Sánchez C. (2018): Appraising the “entourage effect”: Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer. Biochem Pharmacol. 2018 Nov;157:285-293.
Fájdalomra:
Fitzcharles MA, Clauw DJ, Hauser W. (2020): A cautious hope for cannabidiol (CBD) in rheumatology care. Arthritis Care Res (Hoboken).
Boehnke KF, Gagnier JJ, Matallana L, Williams DA. (2021): Cannabidiol Use for Fibromyalgia: Prevalence of Use and Perceptions of Effectiveness in a Large Online Survey. The Journal of Pain, Vol 22, No 5 (May), 2021: pp 556−566
M. Serpell, S. Ratcliffe, J. Hovorka, M. Schofield, L. Taylor5, H. Lauder, E. Ehler (2014): A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment, Eur J Pain 18 (2014) 999–1012
Marija Darkovska-Serafimovska, Tijana Serafimovska, Zorica Arsova-Sarafinovska, Sasho Stefanoski, Zlatko Keskovski, Trajan Balkanov (2018): Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases, Journal of Pain Research 2018:11 837–842
Stressz csökkentésére:
Ila M. Linares, Antonio W. Zuardi, Luis C. Pereira, Regina H. Queiroz, Raphael Mechoulam, Francisco S. Guimara˜es, Jose´ A. Crippa (2018): Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test, Braz J Psychiatry. 2018;00:000-000.
Shannon S, Oplia-Lehman J. (2016): Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: A case report. Perm J Fall; 20(4):16-005.
María S. García-Gutiérrez, Francisco Navarrete, Ani Gasparyan, Amaya Austrich-Olivares, Francisco Sala, Jorge Manzanares (2020): Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders, Biomolecules 2020, 10, 1575
Lucas Elms, Scott Shannon, Shannon Hughes PhD, Nicole Lewis (2018): Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series, THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE Volume 00, Number 00, 2018, pp. 1–6
Daganatos megbetegedésekre:
Blake A, Wan BA, Malek L, DeAngelis C, Diaz P, Lao N, Chow E, O’Hearn S. (2017): A selective review of medical cannabis in cancer pain management. Ann Palliat Med 2017;6(Suppl 2):S215-S222.
Jeremy R. Johnson, Mary Burnell-Nugent, Dominique Lossignol, Elena Doina Ganae-Motan, Richard Potts, Marie T. Fallon (2010): Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain, Journal of Pain and Symptom Management, Vol. 39 No. 2 February 2010
Chris Twelves, Michael Sabel, Daniel Checketts, Sharon Miller, Bola Tayo, Maria Jove, Lucy Brazil, Susan C. Short (2021): A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma, British Journal of Cancer (2021) 124:1379–1387
Paola Massi, Marta Solinas, Valentina Cinquina, Daniela Parolaro (2012): Cannabidiol as potential anticancer drug, British Journal of Clinical Pharmacology 2012, 75:2, page 303–31
Borrelli F, Pagano E, Romano B, Panzera S, Maiello F, Coppola D, De Petrocellis L, Buono L, Orlando P, Izzo AA. (2014): Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. Carcinogenesis. 2014 Dec;35(12):2787-97.
Tamara T. Lah, Metka Novak, Milagros A. Pena Almidon, Oliviero Marinelli, Barbara Žvar Baškovic, Bernarda Majc, Mateja Mlinar, Roman Bošnjak, Barbara Breznik, Roby Zomer, Massimo Nabissi (2021): Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma, Cells 2021, 10, 340.
Idegrendszerre:
Peter Flachenecker, Thomas Henze, Uwe K. Zettl (2014): Nabiximols (THC/CBD Oromucosal Spray, Sativex ®) in Clinical Practice – Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity, Eur Neurol 2014;71:271–279
Orrin Devinsky, Eric Marsh, Daniel Friedman, Elizabeth Thiele, Linda Laux, Joseph Sullivan, Ian Miller, Robert Flamini, Angus Wilfong, Francis Filloux, Matthew Wong, Nicole Tilton, Patricia Bruno, Judith Bluvstein, Julie Hedlund, Rebecca Kamens, Jane Maclean, Srishti Nangia, Nilika Shah Singhal, Carey A Wilson, Anup Patel, Maria Roberta Cilio (2015): Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial, Lancet Neurol 2015, published online
Orrin Devinsky, J. Helen Cross, Linda Laux, Eric Marsh, Ian Miller, Rima Nabbout, Ingrid E. Scheffer, Elizabeth A. Thiele, Stephen Wright (2017): Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome, The new england journal of medicine, vol. 376 no. 21
Susan J. Thanabalasingam, Brandan Ranjith, Robyn Jackson, Don Thiwanka Wijeratne (2021): Cannabis and its derivatives for the use of motor symptoms in Parkinson’s disease: a systematic review and meta-analysis, Ther Adv Neurol Disord 2021, Vol. 14: 1–22
Federal Drug Administration (2020): FDA Approves New Indication for Drug Containing an Active Ingredient Derived from Cannabis to Treat Seizuresin Rare Genetic Disease
Valdeolivas S, Navarrete C, Cantarero I, Bellido ML, Muñoz E, Sagredo O. (2015): Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics. 2015 Jan;12(1):185-99.
De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, Stott CG, Di Marzo V. (2011): Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011 Aug;163(7):1479-94.
Vérkeringés:
Sultan SR, O’Sullivan SE, England TJ. (2020): The effects of acute and sustained cannabidiol dosing for seven days on the haemodynamics in healthy men: A randomised controlled trial. Br J Clin Pharmacol. 2020;1–14.
Khalid A. Jadoon, Garry D. Tan, Saoirse E. O’Sullivan (2017): A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study, JCI Insight. 2017;2(11):e93760
Nyugtató hatás:
Malvika Kaul, Phyllis C. Zee, Ashima S. Sahni (2021): Effects of Cannabinoids on Sleep and their Therapeutic Potential for Sleep Disorders, Neurotherapeutics (2021) 18:217–227
Suraev AS, Marshall NS, Vandrey R, McCartney D, Benson MJ, McGregor IS, Grunstein RR, Hoyos CM (2020): Cannabinoid therapies in the management of sleep disorders: a systematic review of preclinical and clinical studies, Sleep Medicine Reviews
Kesner AJ, Lovinger DM. (2020): Cannabinoids, Endocannabinoids and Sleep. Front Mol Neurosci. 2020 Jul 22;13:125.
Függőség kezelése:
Gustavo Gonzalez-Cuevas, Remi Martin-Fardon, Tony M. Kerr, David G. Stouffer, Loren H. Parsons, Dana C. Hammell, Stan L. Banks, Audra L. Stinchcomb and Friedbert Weiss (2018): Unique treatment potential of cannabidiol for the prevention of relapse to drug use: Preclinical proof of principle, Neuropsychopharmacology
Yasmin L. Hurd, Ph.D., Sharron Spriggs, M.A., Julia Alishayev, R.P.A., Gary Winkel, Ph.D., Kristina Gurgov, R.P.A., Chris Kudrich, D.H.Sc., Anna M. Oprescu, M.P.H., Edwin Salsitz, M.D. (2019): Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial, published online at ajp.psychiatryonline.org
Bőrproblémák:
Attila Oláh, Balázs I. Tóth, István Borbíró, Koji Sugawara, Attila G. Szöllõsi, Gabriella Czifra, Balázs Pál, Lídia Ambrus, Jennifer Kloepper, Emanuela Camera, Matteo Ludovici, Mauro Picardo, Thomas Voets, Christos C. Zouboulis, Ralf Paus, Tamás Bíró (2014): Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes, J Clin Invest. 2014;124(9):3713–3724.
Sangiovanni E, Fumagalli M, Pacchetti B, et al. (2019): Cannabis sativa L. extract and cannabidiol inhibit in vitro mediators of skin inflammation and wound injury. Phytotherapy Research. 2019;1–11.
Sudhir M Baswan, Allison E Klosner, Kelly Glynn, Arun Rajgopal, Kausar Malik, Sunghan Yim, Nathan Stern (2020): Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders, Clinical, Cosmetic and Investigational Dermatology 2020:13 927–942
Sinemyiz Atalaya, Agnieszka G˛egoteka, Adam Wro´nskib, Pedro Domiguesc,El˙zbieta Skrzydlewskaa (2021): Therapeutic application of cannabidiol on UVA and UVB irradiated ratskin. A proteomic study, Journal of Pharmaceutical and Biomedical Analysis 192 (2021) 113656
Cukorbetegség kezelésére
Christian Lehmanna, Nicholas B. Fishere, Barna Tugwellf, Anna Szczesniakb, Mel Kellyb and Juan Zhoua (2016): Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes, Clinical Hemorheology and Microcirculation, vol. 64, no. 4, pp. 655-662, 2016
L Weiss, M Zeira, S Reich, M Har-Noy, R Mechoulam, S Slavin, R Gallily (2006): Cannabidiol lowers incidence of diabetes in non-obese diabetic mice, Autoimmunity. 2006 Mar;39(2):143-51.
Lola Weiss, Michael Zeira, Shoshana Reich, Shimon Slavin, Itamar Raz, Raphael Mechoulam, Ruth Gallily (2008): Cannabidiol arrests onset of autoimmune diabetes in NOD mice, Neuropharmacology 54 (2008) 244-249
Rosszullét
E.M. Rock, L.A. Parker (2017): The Role of 5-HT1A Receptor, and Nausea and Vomiting Relief by Cannabidiol (CBD), Cannabidiolic Acid (CBDA), and Cannabigerol (CBG), Handbook of Cannabis and Related Pathologies, chapter 72
How R, Valdez C, Chow N, Zhang D, Im J, Sodhi E, Lock M. (2020): Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis. Support Care Cancer. 2020 May;28(5):2095-2103.
Antibakteriális hatás
Appendino G, Gibbons S, Giana A, Pagani A, Grassi G, Stavri M, Smith E, Rahman MM. (2008): Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. J Nat Prod. 2008 Aug;71(8):1427-30.
Nachnani R, Raup-Konsavage WM, Vrana KE. (2021): The Pharmacological Case for Cannabigerol. J Pharmacol Exp Ther. 2021 Feb;376(2):204-212.
Gyulladáscsökkentés
Navarro G, Varani K, Reyes-Resina I, Sánchez de Medina V, Rivas-Santisteban R, Sánchez-Carnerero Callado C, Vincenzi F, Casano S, Ferreiro-Vera C, Canela EI, Borea PA, Nadal X, Franco R. (2018): Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1-CB2 Heteroreceptor Complexes. Front Pharmacol. 2018 Jun 21;9:632.
Borrelli F, Fasolino I, Romano B, Capasso R, Maiello F, Coppola D, Orlando P, Battista G, Pagano E, Di Marzo V, Izzo AA. (2013): Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol. 2013 May 1;85(9):1306-16.
Glaukóma
S. Pinar-Sueiro, R. Rodríguez-Puertas, E. Vecino (2011): Cannabinoid applications in glaucoma, Archivos de la Sociedad Española de Oftalmología (English Edition), Volume 86, Issue 1, 2011, Pages 16-23, ISSN 2173-5794,
Tomi Järvinen, David W Pate, Krista Laine (2002): Cannabinoids in the treatment of glaucoma, Pharmacology & Therapeutics, Volume 95, Issue 2, 2002, Pages 203-220, ISSN 0163-7258,
Nucci C, Bari M, Spanò A, Corasaniti M, Bagetta G, Maccarrone M, Morrone LA. (2008): Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection. Prog Brain Res. 2008;173:451-64.
Buchwald A, Browne CE, Wu WM, Ji F, Bodor N. (2000): Soft cannabinoid analogues as potential anti-glaucoma agents. Pharmazie. 2000 Mar;55(3):196-201.
Csontnövekedés
Apostu D, Lucaciu O, Mester A, Benea H, Oltean-Dan D, Onisor F, Baciut M, Bran S. (2019): Cannabinoids and bone regeneration. Drug Metab Rev. 2019 Feb;51(1):65-75.
Bab I, Zimmer A. (2008): Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol. 2008 Jan;153(2):182-8.
Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, Zimmer A, Bab I. (2006): Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):696-701.
Idris AI. (2008): Role of cannabinoid receptors in bone disorders: alternatives for treatment. Drug News Perspect. 2008 Dec;21(10):533-40.
Étvágynövelés
Brierley DI, Samuels J, Duncan M, Whalley BJ, Williams CM. (2016): Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats. Psychopharmacology (Berl). 2016 Oct;233(19-20):3603-13.
Farrimond JA, Mercier MS, Whalley BJ, Williams CM. (2011): Cannabis sativa and the endogenous cannabinoid system: therapeutic potential for appetite regulation. Phytother Res. 2011 Feb;25(2):170-88.
Kirkham TC. (2005): Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol. 2005 Sep;16(5-6):297-313.